Genetic and Epigenetic Determinants of AML Pathogenesis

Overview

Journal Semin Hematol

Specialty Hematology

Date 2019 Mar 31

PMID 30926095

Citations 51

Authors

Sheng F Cai

Ross L Levine

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) was one of the first cancers to be sequenced at the level of the whole genome. Molecular profiling of AML through targeted sequencing panels and cytogenetics has become a mainstay in risk-stratifying AML patients and guiding clinicians toward optimal therapies for their patients. The extensive high-resolution genomic data generated to characterize AML have been instrumental in revealing the tremendous biological complexity of the disease, dictated in part by mutational, clonal, and epigenetic heterogeneity. This is further complicated by the antecedent nonleukemic state of clonal hematopoiesis that nevertheless is associated with an increased risk of developing a hematologic malignancy and with a greater risk of mortality from ischemic cardiovascular disease. Here in this review, we discuss developments in the field of AML biology and therapeutics, with a focus on advances in our understanding of how genetic and epigenetic determinants of AML have influenced prognostication and recent shifts in treatment paradigms, particularly within the context of precision oncology, for this highly complex group of hematologic malignancies.

Citing Articles

Targeting autophagy: polydatin's role in inducing cell death in AML.

Fu P, Luo Q, Wang C, Chen L, Dong C, Yang K Front Pharmacol. 2024; 15:1470217.

PMID: 39629073 PMC: 11613146. DOI: 10.3389/fphar.2024.1470217.

Non-Mutational Changes of Autophagy Marker LC3A in Patients with Acute Myeloid Leukemia; Effect of DNA Methylation and Expression Level of LncRNA-GAS5 and miRNA-155-5p, A Case Control Study.

Amiri V, Mirzaeian A, Noroozi-Aghideh A Indian J Hematol Blood Transfus. 2024; 40(4):621-628.

PMID: 39469184 PMC: 11512980. DOI: 10.1007/s12288-024-01765-3.

Epigenetic-based differentiation therapy for Acute Myeloid Leukemia.

Jose-Eneriz E, Gimenez-Camino N, Rabal O, Garate L, Miranda E, Gomez-Echarte N Nat Commun. 2024; 15(1):5570.

PMID: 38956053 PMC: 11219871. DOI: 10.1038/s41467-024-49784-y.

The Clinical Profile of Newly Diagnosed Acute Myeloid Leukemia at a Tertiary Care Center in South India: A Cross-Sectional Study.

Hari V, Nallathambi N, Y V, A K, Naidu S Cureus. 2024; 16(5):e61234.

PMID: 38939268 PMC: 11210435. DOI: 10.7759/cureus.61234.

CSRP1 gene: a potential novel prognostic marker in acute myeloid leukemia with implications for immune response.

Zhao C, Wang Y, Wang H, Sharma A, Wu Y, Schmidt-Wolf I Discov Oncol. 2024; 15(1):248.

PMID: 38937285 PMC: 11211298. DOI: 10.1007/s12672-024-01088-9.

References

Russler-Germain D, Spencer D, Young M, Lamprecht T, Miller C, Fulton R . The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014; 25(4):442-54. PMC: 4018976. DOI: 10.1016/j.ccr.2014.02.010. View

Agathocleous M, Meacham C, Burgess R, Piskounova E, Zhao Z, Crane G . Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017; 549(7673):476-481. PMC: 5910063. DOI: 10.1038/nature23876. View

Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S . Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999; 82(2-3):293-301. DOI: 10.1016/s0163-7258(99)00005-4. View

Bowman R, Busque L, Levine R . Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell. 2018; 22(2):157-170. PMC: 5804896. DOI: 10.1016/j.stem.2018.01.011. View

Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I . p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994; 84(9):3148-57. View

Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin G, Wang J . Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017; 170(6):1079-1095.e20. PMC: 5755977. DOI: 10.1016/j.cell.2017.07.032. View

Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379(9825):1508-16. DOI: 10.1016/S0140-6736(12)60485-1. View

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

Bhola P, Mar B, Lindsley R, Ryan J, Hogdal L, Vo T . Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016; 126(10):3827-3836. PMC: 5096802. DOI: 10.1172/JCI82908. View

10.

Coombs C, Zehir A, Devlin S, Kishtagari A, Syed A, Jonsson P . Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. 2017; 21(3):374-382.e4. PMC: 5591073. DOI: 10.1016/j.stem.2017.07.010. View

11.

Petersdorf S, Kopecky K, Slovak M, Willman C, Nevill T, Brandwein J . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-60. PMC: 3682338. DOI: 10.1182/blood-2013-01-466706. View

12.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars F, Al Hinai A, Zeilemaker A . Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018; 378(13):1189-1199. DOI: 10.1056/NEJMoa1716863. View

13.

Friedman A, Letai A, Fisher D, Flaherty K . Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015; 15(12):747-56. PMC: 4970460. DOI: 10.1038/nrc4015. View

14.

Stone R, Larson R, Dohner H . Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017; 377(19):1903. DOI: 10.1056/NEJMc1711340. View

15.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson S . Promoter-bound METTL3 maintains myeloid leukaemia by mA-dependent translation control. Nature. 2017; 552(7683):126-131. PMC: 6217924. DOI: 10.1038/nature24678. View

16.

Kim H, Gerhard B, Harasym T, Mayer L, Hogge D . Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011; 39(7):741-50. DOI: 10.1016/j.exphem.2011.04.001. View

17.

Fathi A, DiNardo C, Kline I, Kenvin L, Gupta I, Attar E . Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol. 2018; 4(8):1106-1110. PMC: 5885269. DOI: 10.1001/jamaoncol.2017.4695. View

18.

Young A, Challen G, Birmann B, Druley T . Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016; 7:12484. PMC: 4996934. DOI: 10.1038/ncomms12484. View

19.

Welch J, Ley T, Link D, Miller C, Larson D, Koboldt D . The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2):264-78. PMC: 3407563. DOI: 10.1016/j.cell.2012.06.023. View

20.

DiNardo C, Pratz K, Letai A, Jonas B, Wei A, Thirman M . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(2):216-228. DOI: 10.1016/S1470-2045(18)30010-X. View